- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00442832
TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
January 15, 2021 updated by: Theravance Biopharma
A Phase 2, Randomized, Double Blind, Study of Intravenous TD 1792 Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections
The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
TD-1792 is compared to vancomycin for the treatment of cSSSI.
Study Type
Interventional
Enrollment (Actual)
203
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
National City, California, United States, 91950
- Allan Churukian
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- major abscess requiring surgical incision and drainage,infected burn, deep/extensive cellulitis, infected ulcer, wound infections
- requires at least 7 days of intravenous antibiotic treatment
Exclusion Criteria:
- more than 24 hours of antibiotic therapy
- moderate or severe liver disease
- severely neutropenic
- baseline QTc > 500 msec, congenital long QT syndrome, uncompensated heart failure, uncorrected abnormal K+ or Mg++ blood levels or severe left ventricular hypertrophy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Vancomycin
|
Vancomycin 1 Gm IV q 12 hrs
|
EXPERIMENTAL: TD-1792
|
TD-1792 2 mg/kg/day IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical response
Time Frame: 7 to 14 days after last antibiotic dose
|
7 to 14 days after last antibiotic dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (ACTUAL)
May 1, 2007
Study Completion (ACTUAL)
May 1, 2007
Study Registration Dates
First Submitted
February 28, 2007
First Submitted That Met QC Criteria
February 28, 2007
First Posted (ESTIMATE)
March 2, 2007
Study Record Updates
Last Update Posted (ACTUAL)
January 20, 2021
Last Update Submitted That Met QC Criteria
January 15, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Inflammation
- Disease Attributes
- Connective Tissue Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Staphylococcal Infections
- Suppuration
- Skin Diseases, Bacterial
- Infections
- Communicable Diseases
- Cellulitis
- Skin Diseases, Infectious
- Staphylococcal Skin Infections
- Anti-Infective Agents
- Anti-Bacterial Agents
- Vancomycin
Other Study ID Numbers
- 0041
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcal Skin Infection
-
Aaron ChenJohns Hopkins University; Thrasher Research FundCompletedStaphylococcal Skin Infection | Abscess | Staphylococcal Infection | FolliculitisUnited States
-
Washington University School of MedicineCompletedStaphylococcal Skin Infection | Abscess | Furunculosis | Staphylococcus Aureus | MRSA InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...TerminatedStaphylococcal Aureus Infection | Recurrent Staphylococcal Infection | Invasive Staphylococcal InfectionUnited States
-
Cumberland PharmaceuticalsCompletedStaphylococcal Skin InfectionUnited States
-
Cumberland PharmaceuticalsCompletedStaphylococcal Skin InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedStaphylococcal InfectionUnited States
-
PfizerCompletedBacterial Infections | Staphylococcal Skin Infections | Staphylococcal Infections | Staphylococcal Vaccines | Immunotherapy, ActiveAustralia
-
National Institute of Allergy and Infectious Diseases...CompletedStaphylococcus Aureus Skin InfectionUnited States
-
Washington University School of MedicineCompletedFurunculosis | Staphylococcus Aureus | MRSA Infection | Staphylococcal Skin Infections | AbscessesUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedStaphylococcal InfectionUnited States
Clinical Trials on TD-1792
-
JANSSEN Alzheimer Immunotherapy Research & Development...Wyeth is now a wholly owned subsidiary of PfizerTerminatedAlzheimer's DiseaseUnited States
-
Theravance BiopharmaCompletedInflammatory Bowel Diseases | IBDUnited States
-
Theravance BiopharmaCompletedBowel Diseases, Inflammatory | Intestinal DisordersUnited States
-
Boryung Biopharma Co., Ltd.CompletedTetanus | DiphtheriaKorea, Republic of
-
Theravance BiopharmaTerminatedUlcerative Colitis (UC)United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
-
Theravance BiopharmaCompletedAcute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)United States
-
Theravance BiopharmaCompleted
-
Theravance BiopharmaTerminatedUlcerative Colitis (UC)United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
-
Theravance BiopharmaCompletedParkinson Disease | Orthostatic Hypotension | Neurogenic Orthostatic Hypotension | Hypotension, Orthostatic | Pure Autonomic Failure | Multiple System Atrophy (MSA) With Orthostatic Hypotension | Pure Autonomic Failure With Orthostatic Hypotension | Parkinson Disease With Orthostatic HypotensionUnited States